tiprankstipranks
Trending News
More News >

Alto Neuroscience highlights study results guiding ALTO-207 development

Alto Neuroscience (ANRO) highlighted the publication of data from the PAX-D study in The Lancet Psychiatry, evaluating pramipexole in patients with treatment-resistant depression. The study, funded by the U.K. government, showed pramipexole augmentation demonstrated a large reduction in symptoms relative to placebo at 12 weeks but had a high rate of adverse effects. The study results guided Alto’s acquisition of ALTO-207, a fixed-dose combination of pramipexole and ondansetron designed to mitigate dose-limiting adverse events. Alto plans to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1